ST香雪(300147.SZ)：TAEST16001注射液获得了晚期食管癌和晚期非小细胞肺癌的临床许可

Core Viewpoint - ST Xiangxue's subsidiary is advancing its drug development pipeline with two new drugs, TAEST16001 and TAEST1901, targeting various cancers, indicating a strong focus on oncology research and potential market opportunities [1] Drug Development Progress - TAEST16001 injection is currently undergoing confirmatory clinical trials for the treatment of advanced soft tissue sarcoma [1] - TAEST1901 injection is in Phase I clinical research for advanced liver cancer [1] - TAEST16001 has also received clinical approval for advanced esophageal cancer and advanced non-small cell lung cancer [1] - TAEST1901 has obtained clinical approval for advanced gastric cancer [1]